Meeder Asset Management Inc Acelrx Pharmaceuticals Inc Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$0.49 - $1.02 $127 - $266	-261 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$0.93 - $1.51 $3 - $6	-4 Reduced 1.51%	261 $0
Q1 2021 Apr 28, 2021	BUY	$1.25 - $2.77 $331 - $734	265 New	265 $0
Q4 2020 Feb 09, 2021	SELL	$1.18 - $1.98 $23,018 - $38,623	-19,507 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$1.03 - $1.69 $1,653 - $2,712	-1,605 Reduced 7.6%	19,507 $24,000
Q1 2020 May 15, 2020	BUY	$0.76 - $2.07 $13,776 - $37,522	18,127 Added 607.27%	21,112 $25,000
Q4 2019 Feb 13, 2020	SELL	$1.66 - $2.4 $351 - $508	-212 Reduced 6.63%	2,985 $6,000
Q3 2019 Oct 17, 2019	SELL	$2.1 - $2.87 $2,150 - $2,938	-1,024 Reduced 24.26%	3,197 $7,000
Q2 2019 Aug 05, 2019	BUY	$2.1 - $3.93 $6,096 - $11,408	2,903 Added 220.26%	4,221 $11,000
Q4 2018 Jan 17, 2019	SELL	$2.13 - $4.8 $7,755 - $17,476	-3,641 Reduced 73.42%	1,318 $3,000
Q3 2018 Nov 02, 2018	BUY	$2.6 - $4.6 $9,513 - $16,831	3,659 Added 281.46%	4,959 $0
Q4 2017 Feb 02, 2018	BUY	$1.75 - $5.5 $315 - $990	180 Added 16.07%	1,300 $3,000
Q3 2017 Oct 20, 2017	BUY	$2.9 - $4.6 $3,248 - $5,152	1,120	1,120 $5,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.